Opinion|Videos|May 21, 2024
Evaluating CDK4/6 Inhibitor Safety Profiles: An Analysis of Adverse Events
A medical expert compares CDK4/6 inhibitors and discusses the importance of monitoring specific parameters, such as ECGs and laboratory tests, to minimize adverse events associated with each drug.
Advertisement
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Understanding the Risk of Second Primary Cancers After Early Breast Cancer
September 16th 2025
- Encouraging Successful Completion of the Shingles Vaccine Series
September 16th 2025
- A Pharmacist’s View of Emerging CML Treatment
September 4th 2025
- Potential for Precision: Exploring Targeted Therapies in mCRC Care
September 4th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
2
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5